Table 3.
Socio-demographic and clinical characteristics of the samples of studies dealing with switching antipsychotic treatment to lower prolactin.
| Reference | Country | Ethnicity | Age (years) Mean (SD) |
Duration of illness (years) Mean (SD) |
Duration of treatment with PRL-elevating antipsychotic | Substance use | Symptoms (baseline visit) |
|---|---|---|---|---|---|---|---|
| Switch to aripiprazole | |||||||
| Yoon et al., 2016 | Korea | NR | 34.7 (8.0) | 8.4 (7.4) | >1 month | substance abuse or dependence were excluded | stable over 2 months (no changes in CGI-S) |
| Chen et al. 2011 | China | NR | 48.3 (8.2) | 17.9 (9.1) | NR | NR | CGI-S: 5.1 (0.9) |
| Lu et al., 2008 | China (Taiwan) | NR | 31.7 (9.3) | 5.5 (5.4) | NR | NR | CGI-S: 3.4 (0.5) PANSS total: 53.4 (7.7) |
| Lee et al., 2006 | Korea | NR | 35.0 (7.4) | 2.6 (2.3) | >2 months 6.1 (1.8) |
NR | PANSS total: 45.0 (9.0) |
| Switch to olanzapine | |||||||
| Kinon et al., 2006 | USA | 48.1% caucasian 40.7% african 7.4% asian 3.7% hispanic |
40.0 (10.7) | 14.3 (7.9) | NR† | Alcohol or substance abuse were excluded | CGI-S: 3.4 (0.7) PANSS total: 57.5 (16.0) |
| Switch to quetiapine | |||||||
| Nakajima et al., 2005 | Japan | NR | 55.0 (12.0) | 26.6 (11.6) | >1 month | NR | PANSS positive: 12.8 (4.7) PANSS negative: 18.7 (7.0) PANSS general psychopathology: 41.2 (9.9) |
| Takahashi et al., 2003 | Japan | NR | 25.7 (5.1) | NR | 14.6 (5.3) | NR | BPRS: 42.4 (7.6) |
| Switch to paliperidone | |||||||
| Montalvo et al., 2013 | Spain | NR | 26.6 (5.9) | <5 years (early psychosis) | >6 months | NR | PANSS positive: 10.2 (3.5) PANSS negative: 14.2 (4.4) PANSS general psychopathology: 25.5 (4.5) |
| Switch to blonanserin | |||||||
| Kawabe et al., 2013 | Japan and South Korea | NR | 53.9 (8.4) | 31.7 (9.4) | NR | NR | BPRS: 47.8 (8.4) |
Abbreviations: SD= Standard deviation; NR= Not reported; CGI-S= Clinical Global Impression-Severity scale; PANSS= Positive and Negative Syndrome Scale; BPRS= Brief Psychiatric Rating Scale.
†
In the study by Kinon et al. (2006), patients who were switched to olanzapine had a mean (SD) duration of previous drug therapy of 11.9 (8.4) years. However, it was not specified the duration of the last antipsychotic drug treatment.